|Articles|March 1, 2023

Celebrating Women’s History Month 2023

March is Women's History Month. Psychiatric Times™ shares expert discussions about issues in women’s mental health and care for this patient population.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

The Emerging Field of Women's Mental Health: Nonpharmacologic Management of Postpartum Depression

November 25th 2025

Providing Timely, Appropriate Treatment of Postpartum Depression

ByLeah Kuntz

November 21st 2025

Breaking the Cycle: Jail Diversion as an Alternative to Incarceration for Individuals With Co-Occurring Disorders

ByMichèle Haykal, MD,Nidal Moukaddam, MD, PhD

November 19th 2025

Meeting the Needs of Veteran Patients

ByEugene T. Lucas Jr, DNP, CRNP, FNP-BC, APMHNP-BC

November 11th 2025

Invisible Ranks: The Untold Battle for Women Veterans’ Mental Health

ByRodney Villanueva, MD,Morgan Wan, MD,Liliana Gonzalez-Cabrales, MD

November 11th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Celebrating Women’s History Month 2023

Newsletter

Related Content

The Emerging Field of Women's Mental Health: Nonpharmacologic Management of Postpartum Depression

Providing Timely, Appropriate Treatment of Postpartum Depression

Breaking the Cycle: Jail Diversion as an Alternative to Incarceration for Individuals With Co-Occurring Disorders

Meeting the Needs of Veteran Patients

Invisible Ranks: The Untold Battle for Women Veterans’ Mental Health

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

November in Review: Updates on the Psychiatric Treatment Pipeline

Looking Back: Key Insights from November 2025

Lithium Reduces Risk of Suicide and Recurrent Episodes of Bipolar and Major Depressive Disorders

The Truth About Insomnia and Melatonin: Natural Does Not Always Mean Harmless

New Drug Application Submitted for Centanafidine for Treatment of ADHD